Yuh-Shyan Tsai1, Tzong-Shin Tzai, Nan-Hua Chow. 1. Institute of Clinical Medicine, Department of Urology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Abstract
INTRODUCTION: To evaluate the impact of HER2 immunoreactivity on clinical outcome in locally advanced urothelial carcinoma patients who received surgery alone, or methotrexate, vinblastine, epirubicin, and cisplatin (M-VEC) as adjuvant chemotherapy. MATERIALS AND METHODS: We studied 114 formalin-fixed paraffin-embedded specimens obtained from locally advanced urothelial carcinoma patients receiving surgery alone or adjuvant M-VEC. The authors evaluated HER2 immunoreactivity using immunohistochemical staining and explored the influence of pathological parameters and HER2 immunoreactivity on progression-free survival (PFS) and disease-specific overall survival (OS) using univariate and multivariate Cox's analyses. RESULTS: Urothelial carcinoma of the bladder had a significantly higher frequency of HER2 immunoreactivity than that of the upper urinary tract (60.7 vs. 20.7%, p < 0.0001). Overall, nodal status was a strong and independent prognostic indicator for clinical outcome. The HER2 immunoreactivity was significantly associated with PFS (p = 0.02) and disease-specific OS (p = 0.005) in advanced urothelial carcinoma patients. As for patients with adjuvant M-VEC, HER2 immunoreactivity was a significant prognostic factor for PFS (p = 0.03) and disease-specific OS (p = 0.02) using univariate analysis, but not multivariate analysis, and not for patients receiving watchful waiting. CONCLUSIONS: HER2 immunoreactivity might have a limited prognostic value for advanced urothelial carcinoma patients with adjuvant M-VEC. Copyright 2007 S. Karger AG, Basel.
INTRODUCTION: To evaluate the impact of HER2 immunoreactivity on clinical outcome in locally advanced urothelial carcinomapatients who received surgery alone, or methotrexate, vinblastine, epirubicin, and cisplatin (M-VEC) as adjuvant chemotherapy. MATERIALS AND METHODS: We studied 114 formalin-fixed paraffin-embedded specimens obtained from locally advanced urothelial carcinomapatients receiving surgery alone or adjuvant M-VEC. The authors evaluated HER2 immunoreactivity using immunohistochemical staining and explored the influence of pathological parameters and HER2 immunoreactivity on progression-free survival (PFS) and disease-specific overall survival (OS) using univariate and multivariate Cox's analyses. RESULTS:Urothelial carcinoma of the bladder had a significantly higher frequency of HER2 immunoreactivity than that of the upper urinary tract (60.7 vs. 20.7%, p < 0.0001). Overall, nodal status was a strong and independent prognostic indicator for clinical outcome. The HER2 immunoreactivity was significantly associated with PFS (p = 0.02) and disease-specific OS (p = 0.005) in advanced urothelial carcinomapatients. As for patients with adjuvant M-VEC, HER2 immunoreactivity was a significant prognostic factor for PFS (p = 0.03) and disease-specific OS (p = 0.02) using univariate analysis, but not multivariate analysis, and not for patients receiving watchful waiting. CONCLUSIONS:HER2 immunoreactivity might have a limited prognostic value for advanced urothelial carcinomapatients with adjuvant M-VEC. Copyright 2007 S. Karger AG, Basel.
Authors: Klaus Aumayr; Tobias Klatte; Barbara Neudert; Peter Birner; Shahrokh Shariat; Manuela Schmidinger; Martin Susani; Andrea Haitel Journal: Pathol Oncol Res Date: 2017-07-28 Impact factor: 3.201
Authors: Petros D Grivas; Kathleen C Day; Andreas Karatsinides; Alyssa Paul; Nazia Shakir; Iya Owainati; Monica Liebert; Lakshmi P Kunju; Dafydd Thomas; Maha Hussain; Mark L Day Journal: Mol Med Date: 2013-11-08 Impact factor: 6.354